For many years, it was thought that bacterial products caused fever via the intermediate production of a host-derived, fever-producing molecule, called endogenous pyrogen (EP). Bacterial products and other fever-producing substances were termed exogenous pyrogens. It was considered highly unlikely that exogenous pyrogens caused fever by acting directly on the hypothalamic thermoregulatory center since there were countless fever-producing microbial products, mostly large molecules, with no common physical structure. In vivo and in vitro, lipopolysaccharides (LPSs) and other microbial products induced EP, subsequently shown to be interleukin-1 (IL-1). The concept of the `endogenous pyrogen' cause of fever gained considerable support when pure, recombinant IL-1 produced fever in humans and in animals at subnanomolar concentrations. Subsequently, recombinant tumor necrosis factor-α (TNF-α), IL-6 and other cytokines were also shown to cause fever and EPs are now termed pyrogenic cytokines. However, the concept was challenged when specific blockade of either IL-1 or TNF activity did not diminish the febrile response to LPS, to other microbial products or to natural infections in animals and in humans. During infection, fever could occur independently of IL-1 or TNF activity. The cytokine-like property of Toll-like receptor (TLR) signal transduction provides an explanation by which any microbial product can cause fever by engaging its specific TLR on the vascular network supplying the thermoregulatory center in the anterior hypothalamus. Since fever induced by IL-1, TNF-α, IL-6 or TLR ligands requires cyclooxygenase-2, production of prostaglandin E2 (PGE 2) and activation of hypothalamic PGE2 receptors provides a unifying mechanism for fever by endogenous and exogenous pyrogens. Thus, fever is the result of either cytokine receptor or TLR triggering; in autoimmune diseases, fever is mostly cytokine mediated whereas both cytokine and TLR account for fever during infection.
Beeson PBTemperature-elevating effect of a substance obtained from polymorphonuclear leucocytes (abstract). J Clin Invest1948; 27: 524.
2.
Atkins E.Pathogenesis of fever. Physiol Rev1960; 40: 580—646.
3.
Poltorak A., He X., Smirnova I. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science1998; 282: 2085—2088.
4.
Gay NJ, Keith FJDrosophila Toll and IL-1 receptor. Nature1991; 351: 355—356.
5.
Li S., Ballou LR, Morham SG et al. Cyclooxygenase-2 mediates the febrile response of mice to interleukin-1beta . Brain Res2001; 910: 163—173.
6.
Li S., Goorha S., Ballou LR et al. Intracerebroventricular interleukin-6, macrophage inflammatory protein-1 beta and IL-18: pyrogenic and PGE(2)-mediated?Brain Res2003; 992: 76—84.
7.
Li S., Wang Y., Matsumura K. et al. The febrile response to lipopolysaccharide is blocked in cyclooxygenase-2(—/—), but not in cyclooxygenase-1(—/—) mice. Brain Res1999; 825: 86—94.
8.
Chai Z., Gatti S., Toniatti C. et al. Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1 beta: a study on IL-6-deficient mice. J Exp Med1996; 183: 311—316.
9.
Ushikubi F., Segi E., Sugimoto Y. et al. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature1998; 395: 281—284.
10.
Dinarello CA , Gatti S., Bartfai T.Fever: links with an ancient receptor. Curr Biol1999; 9: R147—R150.
11.
Tavares E., Minano FJDifferential sensitivities of pyrogenic chemokine fevers to cyclooxygenase isozymes antibodies. Brain Res Bull2002; 59: 181—187.
12.
Laburn HP, Rosendorff C., Willies G. et al. A role for noradrenaline and cyclic AMP in prostaglandin E1 fever. J Physiol (Lond) 1974; 240: 49P—50P.
13.
Laburn HPProstaglandin E1 and fever. S Afr Med J1974 ; Suppl: 40—41.
14.
Sehic E., Blatteis CMBlockade of lipopolysaccharide-induced fever by subdiaphragmatic vagotomy in guinea pigs. Brain Res1996; 726: 160—166.
15.
Xin L., Blatteis CMHypothalamic neuronal responses to interleukin-6 in tissue slices: effects of indomethacin and naloxone. Brain Res Bull1992; 29: 27—35.
16.
Watanabe T. , Saiki Y., Sakata Y.The effect of central angiotensin II receptor blockade on interleukin-1beta- and prostaglandin E-induced fevers in rats: possible involvement of brain angiotensin II receptor in fever induction. J Pharmacol Exp Ther1997; 282: 873—881.
17.
Shimizu H., Miyoshi M., Matsumoto K. et al. The effect of central injection of angiotensin-converting enzyme inhibitor and the angiotensin type 1 receptor antagonist on the induction by lipopolysaccharide of fever and brain interleukin-1beta response in rats . J Pharmacol Exp Ther2004; 308: 865—873.
18.
Saper CB, Breder CDThe neurologic basis of fever. N Engl J Med1994; 330: 1880—1886.
19.
Saper CBNeurobiological basis of fever. Ann NY Acad Sci1998; 856: 90—94.
20.
Dinarello CA, Cannon JG, Wolff SM et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med1986; 163: 1433—1450.
21.
Dinarello CA, Cannon JG, Mancilla J. et al. Interleukin-6 as an endogenous pyrogen: induction of prostaglandin E2 in brain but not in peripheral blood mononuclear cells. Brain Res1991; 562: 199—206.
22.
Shapiro L., Zhang X-X., Rupp RG et al. Ciliary neurotrophic factor is an endogenous pyrogen. Proc Natl Acad Sci USA1993; 90: 8614—8618.
23.
Dinarello CA, Bernheim HA, Duff GW et al. Mechanisms of fever induced by recombinant human interferon. J Clin Invest1984; 74: 906—913.
24.
Browning JL , Ribolini A.Interferon blocks interleukin 1-induced prostaglandin release from human peripheral monocytes. J Immunol1987; 138: 2857—2863.
25.
Reznikov LL , Kim SH, Westcott JY et al. IL-18 binding protein increases spontaneous and IL-1-induced prostaglandin production via inhibition of IFN-gamma. Proc Natl Acad Sci USA2000; 97: 2174—2179.
26.
Gatti S., Beck J., Fantuzzi G. et al. Effect of interleukin-18 on mouse core body temperature. Am J Physiol2002; 282: R702—R709.
27.
Kubota T., Fang J., Brown RA et al. Interleukin-18 promotes sleep in rabbits and rats. Am J Physiol2001; 281: R828—R838.
28.
Lee JK, Kim SH, Lewis EC, Azam T., Reznikov LL, Dinarello CADifferences in signaling pathways by IL-1β and IL-18. Proc Natl Acad Sci USA2004; 101: 8815—8820.
29.
Mier JW, Vachino G., van der Meer JW et al. Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients . J Clin Immunol1988; 8: 426—436.
30.
Wolff SMBiological effects of bacterial endotoxins in man. J Infect Dis1973; 128 (Suppl): 733—758.
31.
Greisman SE , Hornick RBComparative pyrogenic reactivity of rabbit and man to bacterial endotoxin. Proc Soc Exp Biol Med1969; 131: 1154—1158.
32.
Dinarello CA , Cannon JG, Mier JW et al. Multiple biological activities of human recombinant interleukin 1. J Clin Invest1986 ; 77: 1734—1739.
33.
Alheim K., Chai Z., Fantuzzi G. et al. Hyperresponsive febrile reactions to interleukin (IL) 1alpha and IL-1beta, and altered brain cytokine mRNA and serum cytokine levels, in IL-1beta-deficient mice. Proc Natl Acad Sci USA1997; 94: 2681—2686.
34.
Laughlin MJ , Kirkpatrick G., Sabiston N. et al. Hematopoietic recovery following high-dose combined alkylating-agent chemotherapy and autologous bone marrow support in patients in phase I clinical trials of colony stimulating factors: G-CSF, GM-CSF, IL-1, IL-2 and M-CSF. Ann Hematol1993; 67: 267—276.
35.
Tewari A., Buhles Jr WC, Starnes Jr HF. Preliminary report: effects of interleukin-1 on platelet counts. Lancet1990; 336: 712—714.
36.
Ogilvie AC, Hack CE, Wagstaff J. et al. IL-1 beta does not cause neutrophil degranulation but does lead to IL- 6, IL-8, and nitrite/nitrate release when used in patients with cancer . J Immunol1996; 156: 389—394.
37.
Nemunaitis J., Ross M., Meisenberg B. et al. Phase I study of recombinant human interleukin-1 beta (rhIL-1 beta) in patients with bone marrow failure. Bone Marrow Transplant1994; 14: 583—588.
38.
Crown J., Jakubowski A., Gabrilove J.Interleukin-1: biological effects in human hematopoiesis. Leukoc Lymphoma1993; 9: 433—440.
39.
Smith JW, Longo D., Alford WG et al. The effects of treatment with interleukin-1a on platelet recovery after high-dose carboplatin. N Engl J Med1993; 328: 756—761.
40.
Iizumi T., Sato S., Iiyama T. et al. Recombinant human interleukin-1 beta analogue as a regulator of hematopoiesis in patients receiving chemotherapy for urogenital cancers . Cancer1991; 68: 1520—1523.
41.
Crown J., Jakubowski A., Kemeny N. et al. A phase I trial of recombinant human interleukin-1β alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. Blood1991; 78: 1420—1427.
42.
Smith JW, Urba WJ, Curti BD et al. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol1992; 10: 1141—1152.
43.
Tilg H., Trehu E., Shapiro L. et al. Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humans. Cytokine1994; 6: 215—219.
44.
Bargetzi MJ , Lantz M., Smith CG et al. Interleukin-1 beta induces interleukin-1 receptor antagonist and tumor necrosis factor binding protein in humans. Cancer Res1993; 53: 4010—4013.
45.
van Damme J. , Opdenakker G., De Ley M. et al. Pyrogenic and haematological effects of the interferon-inducing 22K factor (interleukin-1) from human leukocytes . Clin Exp Immunol1986; 66: 303—311.
46.
Zheng H., Fletcher D., Kozak W. et al. Resistance to fever induction and impaired acute-phase response in interleukin-1β deficient mice. Immunity1995; 3: 9—19.
47.
Yoshida K., Taga T., Saito M. et al. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci USA1996; 93: 407—411.
48.
Schindler R. , Mancilla J., Endres S. et al. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood1990; 75: 40—47.
49.
Aderka D., Le JM, Vilcek J.IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol1989; 143: 3517—3523.
50.
Shapiro L., Panayotatos N., Meydani SN et al. Ciliary neurotrophic factor combined with soluble receptor inhibits synthesis of pro-inflammatory cytokines and prostaglandin-E2 in vitro. Exp Cell Res1994; 215: 51—56.
51.
Reznikov LL , Puren AJ, Fantuzzi G. et al. Suppression of endotoxin-inducible cytokines in whole blood from human subjects following single dose of recombinant human interleukin-11. J Endotoxin Res1999 ; 5: 197—204.
52.
Imrie KR, Sheridan B., Colwill R. et al. A phase I study of interleukin-6 after autologous bone marrow transplantation for patients with poor prognosis Hodgkin's disease. Leukoc Lymphoma1997; 25: 555—563.
53.
Lazarus HM, Winton EF, Williams SF et al. Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer. Bone Marrow Transplant1995; 15: 935—942.
54.
Charles P., Elliott MJ, Davis D. et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol1999; 163: 1521—1528.
55.
Fisher Cjj, Slotman GJ, Opal SM et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med1994; 22: 12—21.
56.
Coceani F., Lees J., Mancilla J. et al. Interleukin-6 and tumor necrosis factor in cerebrospinal fluid: changes during pyrogen fever. Brain Res1993 ; 612: 165—171.
57.
Hauptmann B., Van Damme J, Dayer JMModulation of IL-1 inflammatory and immunomodulatory properties by IL-6. Eur Cytokine Netw1991; 2: 39—46.
58.
Chandrasekharan NV, Dai H., Roos KL et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA2002 ; 99: 13926—13931.
59.
Willoughby DA , Moore AR, Colville-Nash PRCOX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet2000 ; 355: 646—648.
60.
Kozak W., Kluger MJ, Soszynski D. et al. IL-6 and IL-1β in fever. Studies using cytokine-deficient (knockout) mice. Ann NY Acad Sci1998; 856: 33—47.
61.
Fantuzzi G., Zheng H., Faggioni R. et al. Effect of endotoxin in IL-1β-deficient mice. J Immunol1996; 157: 291—296.
62.
Creagan ET, Kovach JS, Moertel CG et al. A phase I clinical trial of recombinant human tumor necrosis factor. Cancer1988; 62: 2467—2471.
63.
Feinberg B. , Kurzrock R., Talpaz M. et al. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol1988; 6: 1328—1334.
64.
Brown TD, Goodman P., Fleming T. et al. A phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of the pancreas: a Southwest Oncology Group study. J Immunother1991; 10: 376—378.
65.
Budd GT, Green S., Baker LH et al. A Southwest Oncology Group phase II Trial of recombinant tumor necrosis factor in metastatic breast cancer. Cancer1991; 68: 1694—1695.
66.
Smith JW, Urba WJ, Curti BD et al. Phase II trial of interleukin-1 alpha in combination with indomethacin in melanoma patients (abstract). Proc Am Soc Clin Oncol1991; 10: 293.
67.
Moore MARole of interleukin-1 in hematopoiesis. Immunol Res1989; 8: 165—175.
68.
Dinarello CABiological basis for interleukin-1 in disease . Blood1996; 87: 2095—2147.
69.
van der Poll T., van Deventer SJ, Hack CE et al. Effects on leukocytes after injection of tumor necrosis factor into healthy humans. Blood1992; 79: 693—698.
70.
Sherman ML, Spriggs DR, Arthur KA et al. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol1988; 6: 344—350.
71.
Gabay C., Kushner I.Acute-phase proteins and other systemic responses to inflammation. N Engl J Med1999; 340: 448—454.
72.
Ghezzi P., Saccardo B., Bianchi M.Recombinant tumor necrosis factor depresses cytochrome P450-dependent microsomal drug metabolism in mice. Biochem Biophys Res Commun1986; 136: 316—321.
73.
Tilg H., Trehu E., Atkins MB et al. Interleukin-6 (IL-6) as an antiinflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood1994; 83: 113—118.
74.
Fattori E., Cappelletti M., Costa P. et al. Defective inflammatory response in interleukin 6-deficient mice . J Exp Med1994; 180: 1243—1250.
75.
Di Santo E. , Alonzi T., Poli V. et al. Differential effects of IL-6 on systemic and central production of TNF: a study with IL-6-deficient mice. Cytokine1997; 9: 300—306.
76.
Blatteis CMRole of the OVLT in the febrile response to circulating pyrogens. Prog Brain Res1992; 91: 409—412.
77.
Rosendorff C.The pathogenesis of fever: neurochemical aspects . Isr J Med Sci1976; 12: 960—973.
78.
Rosendorff C.Neurochemistry of fever. SAfr J Med Sci1976; 41: 23—48.
79.
Rossi V., Breviario F., Ghezzi P. et al. Prostacyclin synthesis induced in vascular cells by interleukin-1 . Science1985; 229: 174—176.
80.
Dustin ML, Rothlein R., Bhan AK et al. Induction by IL 1 and interferon-g: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol1986; 137: 245—254.
81.
Coceani F.Prostaglandins and fever. In: Machowiak P. (ed) Fever: Basic Mechanisms and Management. New York: Raven, 1991; 59—70.
82.
Laflamme N. , Rivest S.Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating Gram-negative bacterial cell wall components. FASEB J2001 ; 15: 155—163.
83.
Matsumura K. , Kaihatsu S., Imai H. et al. Cyclooxygenase in the vagal afferents: is it involved in the brain prostaglandin response evoked by lipopolysaccharide? AutonNeurosci2000; 85: 88—92.
84.
Simons CT, Kulchitsky VA, Sugimoto N. et al. Signaling the brain in systemic inflammation: which vagal branch is involved in fever genesis?Am J Physiol1998; 275: R63—R68.
85.
Szekely M., Balasko M., Kulchitsky VA et al. Multiple neural mechanisms of fever. Auton Neurosci2000; 85: 78—82.
86.
Romanovsky AA, Simons CT, Szekely M. et al. The vagus nerve in the thermoregulatory response to systemic inflammation. Am J Physiol1997; 273: R407—R413.
87.
Romanovsky AA, Ivanov AI, Lenczowski MJ et al. Lipopolysaccharide transport from the peritoneal cavity to the blood: is it controlled by the vagus nerve? AutonNeurosci2000; 85: 133—140.
88.
Kapas L., Hansen MK, Chang HY et al. Vagotomy attenuates but does not prevent the somnogenic and febrile effects of lipopolysaccharide in rats. Am J Physiol1998; 274: R406—R411.
89.
Opp MR, Toth LASomnogenic and pyrogenic effects of interleukin-1beta and lipopolysaccharide in intact and vagotomized rats. Life Sci1998 ; 62: 923—936.
90.
Borovikova LV, Ivanova S., Zhang M. et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature2000; 405: 458—462.
91.
Wang H., Yu M., Ochani M. et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature2003; 421: 384—388.
92.
Ikejima T., Zhang XX, Wen HD et al. IL-1 receptor antagonist reduces IL-1 mediated fever in the rabbit but not LPS or Staphylococcus epidermidis-induced fever (abstract). Clin Res1991; 39: 462.
93.
Dinarello CA, Zhang XX, Wen HD et al. The effect of interleukin-1 receptor antagonist on IL-1, LPS, Staphylococcus epidermidis and tumor necrosis factor fever. In: Bartfai T, Ottoson D. (eds) Neuro-Immunology of Fever. Oxford: Pergammon, 1992; 11—18.
94.
Aiura K., Gelfand JA, Wakabayashi G. et al. Interleukin-1 (IL-1) receptor antagonist prevents Staphylococcus epidermidis-induced hypotension and reduces circulating levels of tumor necrosis factor and IL-1β in rabbits. Infect Immun1993; 61: 3342—3350.
95.
Granowitz EV , Porat R., Mier JW et al. Pharmacokinetics, safety, and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine1992; 4: 353—360.
96.
Antin JH, Weinstein HJ, Guinan EC et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood1994; 84: 1342—1348.
97.
Antin JH, Weisdorf D., Neuberg D. et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation . Blood2002; 100: 3479—3482.
98.
Rock CS, Coyle SM, Keogh CV et al. Influence of hypercortisolemia on the acute-phase protein response to endotoxin in humans. Surgery1992; 112: 467—474.
99.
Preas 2nd HL, Reda D., Tropea M. et al. Effects of recombinant soluble type I interleukin-1 receptor on human inflammatory responses to endotoxin. Blood1996; 88: 2465—2472.
100.
van der Poll T., Jansen J., van Leenen D. et al. Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis1993; 168: 955—960.
101.
Suffredini AF , Reda D., Banks SM et al. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration . J Immunol1995; 155: 5038—5045.
102.
DeLa Cadena RA , Majluf-Cruz A., Stadnicki A. et al. Recombinant tumor necrosis factor receptor p75 fusion protein (TNFR:Fc) alters endotoxin-induced activation of the kinin, fibrinolytic, and coagulation systems in normal humans. Thromb Haemost1998; 80: 114—118.
103.
Dinarello CA, Rosenwasser LJ, Wolff SMDemonstration of a circulating suppressor factor of thymocyte proliferation during endotoxin fever in humans. J Immunol1981; 127: 2517—2519.
104.
Granowitz EV, Porat R., Mier JW et al. Hematological and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans. Blood1993; 82: 2985—2990.
105.
Van Zee KJ , Coyle SM, Calvano SE et al. Influence of IL-1 receptor blockade on the human response to endotoxemia. J Immunol1995; 154: 1499—1507.
106.
Granowitz EV, Santos A., Poutsiaka DD et al. Circulating interleukin-1 receptor antagonist levels during experimental endotoxemia in humans. Lancet1991; 338: 1423—1424.
107.
Moreland LW , Cohen SB, Baumgartner SW et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol2001; 28: 1238—1244.
108.
Leonardi CL , Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med2003; 349: 2014—2022.
109.
Zou J., Rudwaleit M., Brandt J. et al. Up-regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis2003; 62: 561—564.
110.
Fisher Cjj , Dhainaut JF, Opal SM et al. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double blind, placebo-controlled trial. JAMA1994; 271: 1836—1843.
111.
Opal SM, Fisher Cjj, Dhainaut JF et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med1997; 25: 1115—1124.
112.
Abraham E. , Wunderink R., Silverman H. et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis syndrome. JAMA1995; 273: 934—941.
113.
Abraham E. , Anzueto A., Gutierrez G. et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet1998; 351: 929—933.
114.
Reinhart K. , Wiegand-Lohnert C., Grimminger F. et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med1996; 24: 733—742.
115.
Reinhart K. , Karzai W.Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med2001; 29: S121—125.
116.
Fisher Jr C., Agosti JM, Opal SM et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med1996; 334: 1697—1702.
117.
Abraham E. , Laterre PF, Garbino J. et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1342 patients . Crit Care Med2001; 29: 503—510.
118.
Abraham E. , Glauser MP, Butler T. et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA1997; 277: 1531—1538.
119.
Gershenwald JE, Fong YM, Fahey TJ et al. Interleukin 1 receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci USA1990; 87: 4966—4970.
120.
Bujak JS, Aptekar RG, Decker JL et al. Juvenile rheumatoid arthritis presenting in the adult as fever of unknown origin. Rheumatology (Oxford ) 1973; 52: 431—444.
121.
Emmenegger U., Reimers A., Frey U. et al. Reactive macrophage activation syndrome: a simple screening strategy and its potential in early treatment initiation . Swiss Med Wkly2002; 132: 230—236.
122.
Choi JH, Suh CH, Lee YM et al. Serum cytokine profiles in patients with adult onset Still's disease . J Rheumatol2003; 30: 2422—2427.
123.
Maeno N., Takei S., Imanaka H. et al. Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. Arthritis Rheum2004; 50: 1935—1938.
124.
Caramaschi P., Biasi D., Carletto A. et al. A case of adult onset Still's disease treated with infliximab. Clin Exp Rheumatol2002; 20: 113.
125.
Olivieri I. , de Stefano G., Padula A. et al. Infliximab in a case of early adult-onset Still's disease. Clin Rheumatol2003; 22: 369—370.
126.
Kraetsch HG , Antoni C., Kalden JR et al. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences . Ann Rheum Dis2001; 60 (Suppl 3):55—57.
127.
Aeberli D. , Oertle S., Mauron H. et al. Inhibition of the TNFpathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly2002; 132: 414—422.
128.
Kokkinos A. , Iliopoulos A., Greka P. et al. Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients. Clin Rheumatol2004 ; 23: 45—49.
129.
Cavagna L. , Caporali R., Epis O. et al. Infliximab in the treatment of adult Still's disease refractory to conventional therapy. Clin Exp Rheumatol2001; 19: 329—332.
130.
Fitzgerald AA, LeClercq SA, Yan A. et al. Rapid response to anakinra in patients with refractory adult onset Still's disease. Arthritis Rheum2004; 46: In press.
131.
Rudinskaya A., Trock DHSuccessful treatment of a patient with refractory adult-onset Still's disease with anakinra. J Clin Rheumatol2003; 9: 330—332.
132.
Hawkins PN , Lachmann HJ, Aganna E. et al. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum2004; 50: 607—612.
133.
Hoffman HM , Mueller JL, Broide DH et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet2001; 29: 301—305.
134.
Hoffman HM , Wanderer AA, Broide DHFamilial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol2001; 108: 615—620.
135.
Hoffman HM , Gregory SG, Mueller JL et al. Fine structure mapping of CIAS1: identification of an ancestral haplotype and a common FCAS mutation, L353P. Hum Genet2003; 112: 209—216.
136.
Hoffman HM, Wright FA, Broide DH et al. Identification of a locus on chromosome 1q44 for familial cold urticaria. Am J Hum Genet2000; 66: 1693—1698.
137.
Tschopp J., Martinon F., Burns K.NALPs: a novel protein family involved in inflammation. Nat Rev Mol Cell Biol2003; 4: 95—104.
138.
Agostini L., Martinon F., Burns K. et al. NALP3 forms an IL-1β processing inflammasome with increased activity in Muckle-Wells auto-inflammatory disorder. Immunity2004; 20: 319—325.
139.
Lovell DJ, Bowyer SLTreatment of neonatal onset multisystem inflammatory disease (NOMID) with IL-1Ra (anakinra). Arthritis Rheum2003; 48 (Suppl): S517.
140.
Hoffman HM, Rosengren S., Boyle DL et al. Interleukin-1 receptor antagonist prevents cold-associated acute inflammation in familial cold autoinflammatory syndrome. Lancet2004; In press.
141.
Ozen S.Familial Mediterranean fever: revisiting an ancient disease. Eur J Pediatr2003; 162: 449—454.
142.
Chae JJ, Komarow HD, Cheng J. et al. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell2003; 11: 591—604.
143.
Dinarello CA, Wolff SM, Goldfinger SE et al. Colchicine therapy for familial Mediterranean fever — a double blind trial. N Engl J Med1974; 291: 934—937.
144.
Dinarello CA, Chusid MJ, Fauci AS et al. The effect of prophylactic colchicine on leukocytic functions in patients with familial Mediterranean fever. Arthritis Rheum1976; 19: 618—622.
145.
Shoham NG, Centola M., Mansfield E. et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci USA2003; 100: 13501—13506.
146.
Ozen S., Bakkaloglu A., Yilmaz E. et al. Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation?J Rheumatol2003 ; 30: 2014—2018.
147.
Drenth JP, Haagsma CJ, van der Meer JWHyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore) 1994; 73: 133—144.
148.
Drenth JP, Goertz J., Daha MR et al. Immunoglobulin D enhances the release of tumor necrosis factor-alpha, and interleukin-1 beta as well as interleukin-1 receptor antagonist from human mononuclear cells. Immunology1996; 88: 355—362.
149.
Takada K., Aksentijevich I., Mahadevan V. et al. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum2003; 48: 2645—2651.
150.
Simon A., Drewe E., van der Meer JW et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther2004; 75: 476—483.
151.
McDermott MF, Aksentijevich I., Galon J. et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell1999; 97: 133—144.
152.
Galon J., Aksentijevich I., McDermott MF, et al. TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol2000; 12: 479—486.
153.
Shapiro L. , Clark BD, Orencole SF et al. Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic humans . J Infect Dis1993; 167: 1344—1350.
154.
Ulevitch RJ , Tobias PSRecognition of endotoxin by cells leading to transmembrane signaling. Curr Opin Immunol1994; 6: 125—130.
155.
Atkins E.Fever: the old and the new. J Infect Dis1984 ; 149: 339—348.
156.
Murphy PA, Chesney PJ, Wood Jr WBFurther purification of rabbit leukocyte pyrogen. J Lab Clin Med1974; 83: 310—322.
157.
Root RK, Nordlund JJ, Wolff SMFactors affecting the quantitative production and assay of human leukocytic pyrogen. J Lab Clin Med1970; 75: 679—693.
158.
Bodel P.Studies on the mechanism of endogenous pyrogen production. I. Investigation of new protein synthesis in stimulated human blood leucocytes. Yale J Biol Med1970; 43: 145—163.
159.
Nordlund JJ , Root RK, Wolff SMStudies on the origin of human leukocytic pyrogen. J Exp Med1970; 131: 727—743.
160.
Bodel P., Atkins E.Release of endogenous pyrogen by human monocytes. N Engl J Med1967; 276: 1002—1008.
161.
Bodel P., Ralph P., Wenc K. et al. Endogenous pyrogen production by Hodgkin's disease and human histiocytic lymphoma cell lines in vivo. J Clin Invest1980; 65: 514—518.
162.
Bodel PT, Hollingsworth JWPyrogen release from human synovial exudate cells. Br J Exp Pathol1968; 49: 11—19.
163.
Bodel P.Colchicine stimulation of pyrogen production by human blood leukocytes. J Exp Med1976; 143: 1015—1026.
164.
Manie S., Schmid-Alliana A., Kubar J. et al. Disruption of microtubule network in human monocytes induces expression of interleukin-1 but not that of interleukin-6 nor tumor necrosis factor-alpha. Involvement of protein kinase A stimulation. J Biol Chem1993; 268: 13675—13681.
165.
Elin RJ, Wolff SMBiology of endotoxin. Annu Rev Med1976; 27: 127—141.
166.
Revhaug A. , Michie HR, Manson JM et al. Inhibition of cyclooxygenase attenuates the metabolic response to endotoxin in humans. Arch Surg1988; 123: 162—170.
167.
Michie HR, Manogue KR, Spriggs DR et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med1988; 318: 1481—1486.
168.
Michel M., Duvoux C., Hezode C. et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol2003; 30: 1624—1625.
169.
Kimball HR , Melmon ML, Wolff SMEndotoxin-induced kinin production in man . Proc Soc Exp Biol Med1972; 139: 1078—1082.
170.
Dale DC, Fauci AS, Guerry DI et al. Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiocholanolone. J Clin Invest1975; 56: 808—813.
171.
Dinarello CA, Goldin NP, Wolff SMDemonstration and characterization of two distinct human leukocytic pyrogens. J Exp Med1974; 139: 1369—1381.
172.
Murphy PA, Cebula TA, Levin J. et al. Rabbit macrophages secrete two biochemically and immunologically distinct endogenous pyrogens. Infect Immun1981; 34: 177—183.
173.
Hanson DF, Murphy PADemonstration of interleukin 1 activity in apparently homogeneous specimens of the pI 5 form of rabbit endogenous pyrogen. Infect Immun1984; 45: 483—490.
174.
Auron PE, Webb AC, Rosenwasser LJ et al. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci USA1984; 81: 7907—7911.
175.
Lomedico PT , Gubler R., Hellmann CP et al. Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature1984; 312: 458—462.
176.
Coeshott C. , Ohnemus C., Pilyavskaya A. et al. Converting enzyme-independent release of TNF-α and IL-1β from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase-3. Proc Natl Acad Sci USA1999; 96: 6261—6266.
177.
Dinarello CA, Renfer L., Wolff SMHuman leukocytic pyrogen: purification and development of a radioimmunoassay . Proc Natl Acad Sci USA1977; 74: 4624—4627.
178.
Merriman CR, Pulliam LA, Kampschmidt RFComparison of leukocytic pyrogen and leukocytic endogenous mediator. Proc Soc Exp Biol Med1977; 154: 224—227.
179.
Kampschmidt RFLeukocytic endogenous mediator/endogenous pyrogen. In: Powanda MC, Canonico PG. (eds) The Physiologic and Metabolic Responses of the Host. Amsterdam : Elsevier, 1981; 55—74.
180.
McAdam Kpwj, Dinarello CAInduction of serum amyloid A synthesis by human leukocytic pyrogen. In: Agarwal MK. (ed) Bacterial Endotoxins and Host Response. Amsterdam: Elsevier , 1980; 167—178.
181.
Gery I., Waksman BHPotentiation of the T-lymphocyte response to mitogens. II. The cellular source of potentiating mediator(s). J Exp Med1972 ; 136: 143—155.
182.
Rosenwasser LJ, Dinarello CA, Rosenthal ASAdherent cell function in murine T-lymphocyte antigen recognition. IV. Enhancement of murine T-cell antigen recognition by human leukocytic pyrogen. J Exp Med1979 ; 150: 709—714.
183.
Dayer JM, Graham R., Russell G., et al. Collagenase production by rheumatoid synovial cells: stimulation by a human lymphocyte factor. Science1977 ; 195: 181—183.
Westphal O. , Luderitz O., Rietschel ET et al. Bacterial lipopolysaccharide and its lipid A component: some historical and some current aspects. Biochem Soc Trans1981; 9: 191—195.
186.
Rietschel ET, Kim YB, Watson DW et al. Pyrogenicity and immunogenicity of lipid A complexed with bovine serum albumin or human serum albumin. Infect Immun1973; 8: 173—177.
187.
Rietschel ET, Schade U., Jensen M. et al. Bacterial endotoxins: chemical structure, biological activity and role in septicaemia. Scand J Infect Dis Suppl 1982; 31: 8—21.
188.
Luderitz O. , Simmons DA, Westphal G.The immunochemistry of Salmonella chemotype VI O-antigens. The structure of oligosaccharides from Salmonella group U (o-43) lipopolysaccharides. Biochem J1965; 97: 820—826.
189.
Galanos C. , Luderitz O., Westphal O.Preparation and properties of antisera against the lipid-A component of bacterial lipopolysaccharides. Eur J Biochem1971; 24: 116—122.
190.
Cooper KE, Veale WL, Pittman QJMetabolic and other aspects of fever. Isr J Med Sci1976; 12: 955—959.
191.
Pittman QJ , Veale WL, Cooper KEObservations on the effect of salicylate in fever and the regulation of body temperature against cold. Can J Physiol Pharmacol1976; 54: 101—106.
192.
Granowitz EV, Porat R., Gelfand JA et al. Administration of low-dose endotoxin to healthy humans increases C5a binding to circulating neutrophils. J Infect Dis1994; 169: 480—482.
193.
Michie HR, Spriggs DR, Manogue KR et al. Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery1988; 104: 280—286.
194.
Greisman SE , Hornick RBThe nature of endotoxin tolerance. Trans Am Clin Climatol Assoc1975; 86: 43—50.
195.
Greisman SE , Hornick RBMechanisms of endotoxin tolerance with special reference to man. J Infect Dis1973; 128: 265—276.
196.
Mickenberg ID, Snyderman R., Root RK et al. The relationship of complement consumption to immune fever. J Immunol1971; 107: 1466—1476.
197.
Mickenberg ID, Snyderman R., Root RK et al. Immune fever in the rabbit: responses of the hematologic and complement systems. J Immunol1971; 107: 1457—1465.
